Action of Varespladib (LY-315920), a Phospholipase A2 Inhibitor, on the Enzymatic, Coagulant and Haemorrhagic Activities of Lachesis muta rhombeata (South-American Bushmaster) Venom

• Main Authors: Pamella G. Gutierres (Author), Diego R. Pereira (Author), Nataly L. Vieira (Author), Lilian F. Arantes (Author), Nelson J. Silva (Author), Kristian A. Torres-Bonilla (Author), Stephen Hyslop (Author), Karen Morais-Zani (Author), Rosa M. B. Nogueira (Author), Edward G. Rowan (Author), Rafael S. Floriano (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Varespladib (VPL) was primarily developed to treat inflammatory disturbances associated with high levels of serum phospholipase A2 (PLA2). VPL has also demonstrated to be a potential antivenom support agent to prevent PLA2-dependent effects produced by snake venoms. In this study, we examined the ac...